Department of Dermatology, No.1 Hospital of China Medical University, 155 North Nanjing Street, Shenyang 110001, China.
Eur J Dermatol. 2009 Sep-Oct;19(5):474-7. doi: 10.1684/ejd.2009.0727. Epub 2009 Jun 5.
Palmoplantar pustulosis (PPP) is a chronic recurring and refractory pustular dermatosis. To investigate the efficacy and safety of arotinoid ethylester in patients with PPP, sixteen adult subjects with PPP, who had taken no systemic medications for three months, were enrolled. All the subjects received 0.03 mg of arotinoid ethylester once daily as initial dosage. The number of pustules and lesion area index (LAI) were measured pre- and post-treatment. Repeated measures of one factor ANOVA was used to statistically analyze the data. After 3 months of treatment, pustules disappeared completely in all patients (F = 15.04; p < .0001); LAI decreased significantly (F = 24.54; p < .0001). Complete clearance (100% reduction of LAI and complete disappear of pustules) and near complete clearance (75%-99%) occurred in 6 and 8 patients, respectively; the other two patients exhibited partial clearance (50%-74%). Side effects were observed in 10 patients, but were mild to moderate and well tolerated. Our study suggested that arotinoid ethylester is an effective therapy for PPP with minimal side effects.
掌跖脓疱病（PPP）是一种慢性复发性难治性脓疱性皮肤病。为了评估维 A 酸乙酯治疗掌跖脓疱病的疗效和安全性，我们纳入了 16 名成人 PPP 患者，这些患者在入组前的 3 个月内未接受过任何系统性药物治疗。所有患者均接受维 A 酸乙酯 0.03mg，每日一次作为起始剂量。在治疗前和治疗后分别测量脓疱数量和皮损面积指数（LAI）。采用单因素重复测量方差分析对数据进行统计学分析。经过 3 个月的治疗后，所有患者的脓疱均完全消失（F = 15.04；p <.0001）；LAI 显著降低（F = 24.54；p <.0001）。6 名患者完全清除（LAI 减少 100%，脓疱完全消失），8 名患者接近完全清除（LAI 减少 75%-99%）；另外 2 名患者部分清除（LAI 减少 50%-74%）。10 名患者出现不良反应，但均为轻中度，且患者耐受良好。我们的研究表明，维 A 酸乙酯是一种治疗掌跖脓疱病的有效药物，且不良反应最小。
